| scholarly article | Q13442814 |
| P50 | author | Patrick M. Sexton | Q39936838 |
| Denise Wootten | Q43294588 | ||
| P2093 | author name string | Samuel H Gellman | |
| Lisa M Johnson | |||
| Marlies V Hager | |||
| P2860 | cites work | A Hydrogen-Bonded Polar Network in the Core of the Glucagon-Like Peptide-1 Receptor Is a Fulcrum for Biased Agonism: Lessons from Class B Crystal Structures | Q27345100 |
| Structural and biological mimicry of protein surface recognition by / -peptide foldamers | Q27657158 | ||
| Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor | Q27657999 | ||
| Crystal Structures of a Stabilized β1-Adrenoceptor Bound to the Biased Agonists Bucindolol and Carvedilol | Q27679036 | ||
| The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism | Q28276469 | ||
| Characterization of glucagon-like peptide-1 receptor beta-arrestin 2 interaction: a high-affinity receptor phenotype | Q28291820 | ||
| Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration | Q28378259 | ||
| GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells | Q28506327 | ||
| A simple method for quantifying functional selectivity and agonist bias | Q28728741 | ||
| A luminescent biosensor with increased dynamic range for intracellular cAMP | Q84966539 | ||
| Beta-arrestins and cell signaling | Q29616793 | ||
| Biology of incretins: GLP-1 and GIP | Q29617302 | ||
| Seven-transmembrane receptors | Q29619896 | ||
| A β-peptide agonist of the GLP-1 receptor, a class B GPCR. | Q33553641 | ||
| Teaching old receptors new tricks: biasing seven-transmembrane receptors | Q33985759 | ||
| A potent α/β-peptide analogue of GLP-1 with prolonged action in vivo | Q34282783 | ||
| Backbone modification of a polypeptide drug alters duration of action in vivo | Q34385531 | ||
| Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling | Q34963202 | ||
| Actions of the small molecule ligands SW106 and AH-3960 on the type-1 parathyroid hormone receptor | Q35054974 | ||
| Ligand-selective receptor conformations revisited: the promise and the problem | Q35181787 | ||
| Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. | Q35454522 | ||
| Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation | Q35763258 | ||
| Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function. | Q35763289 | ||
| Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects | Q35856484 | ||
| Seven-transmembrane receptor signaling through beta-arrestin | Q36305171 | ||
| Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice | Q36373813 | ||
| Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells | Q36638807 | ||
| Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations | Q36729833 | ||
| Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors | Q36773326 | ||
| Therapeutic potential of β-arrestin- and G protein-biased agonists. | Q36773331 | ||
| Conformational complexity of G-protein-coupled receptors | Q36880905 | ||
| A review of exenatide as adjunctive therapy in patients with type 2 diabetes | Q37403218 | ||
| Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor | Q38016154 | ||
| Signalling bias in new drug discovery: detection, quantification and therapeutic impact. | Q38081692 | ||
| Emerging structural insights into biased GPCR signaling | Q38280044 | ||
| Optical Control of Insulin Secretion Using an Incretin Switch. | Q38818301 | ||
| Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production. | Q40548199 | ||
| Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity | Q41051549 | ||
| Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. | Q42479294 | ||
| Emergent biological properties of arrestin pathway-selective biased agonism | Q46960983 | ||
| Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure | Q47945051 | ||
| A new GLP-1 analogue with prolonged glucose-lowering activity in vivo via backbone-based modification at the N-terminus. | Q50878317 | ||
| Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands. | Q51755093 | ||
| β-Arrestin1-mediated recruitment of c-Src underlies the proliferative action of glucagon-like peptide-1 in pancreatic β INS832/13 cells. | Q54486729 | ||
| Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides | Q70942068 | ||
| Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s) | Q80065293 | ||
| P433 | issue | 45 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 14970-14979 | |
| P577 | publication date | 2016-11-04 | |
| P1433 | published in | Journal of the American Chemical Society | Q898902 |
| P1476 | title | β-Arrestin-Biased Agonists of the GLP-1 Receptor from β-Amino Acid Residue Incorporation into GLP-1 Analogues | |
| P478 | volume | 138 |
| Q96132105 | Advances in therapeutic peptides targeting G protein-coupled receptors |
| Q38864019 | Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1. |
| Q47416630 | Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with Broad β Residue Distribution. |
| Q47260358 | Evaluation of β-Amino Acid Replacements in Protein Loops: Effects on Conformational Stability and Structure. |
| Q92513493 | Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury |
| Q68687096 | O-GlcNAc Engineering of GPCR Peptide-Agonists Improves Their Stability and in Vivo Activity |
| Q89289805 | Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice |
| Q64106173 | Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo |
| Q52375459 | Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex. |
| Q95643214 | The activity of sulfono-γ-AApeptide helical foldamers that mimic GLP-1 |
| Q53282873 | Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism. |
| Q89520120 | Ureidopeptide GLP-1 analogues with prolonged activity in vivo via signal bias and altered receptor trafficking |
Search more.